Skip to main content
SpringerLink
Log in

Myositis Mimics: The Differential Diagnosis of Myositis

  • Chapter
  • First Online:
Managing Myositis

Abstract

Abstract: Autoimmune myopathies are a heterogeneous family of diseases characterized by muscle weakness, elevated serum muscle enzymes, and muscle biopsies revealing inflammation and/or necrosis. Since patients with inherited muscle disease, inclusion body myositis, endocrine myopathies, and toxic myopathies can present with similar clinical features, they may be misdiagnosed with autoimmune myopathy and unnecessarily treated with immunosuppressive agents. Here, we review those entities most likely to be misdiagnosed as an autoimmune myopathy, highlighting features that distinguish them and providing guidance about how to properly diagnose them (Table 23.1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Furst DE, Amato AA, Iorga SR, et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve. 2012;45:676–83.

    Article  PubMed  Google Scholar 

  2. Smoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord. 2012;13:1–13.

    Article  Google Scholar 

  3. Theadom A, Rodrigues M, Roxburgh R, et al. Prevalence of muscular dystrophies: a systematic literature review. Neuroepidemiology. 2014;43:259–68.

    Article  PubMed  Google Scholar 

  4. Norwood FLM, Harling C, Chinnery PF, et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain. 2009;132:3175–86.

    Article  PubMed  Google Scholar 

  5. Cardamone M, Darras BT, Ryan MM. Inherited myopathies and muscular dystrophies. Semin Neurol. 2008;28:250–9.

    Article  PubMed  Google Scholar 

  6. Schoser B, Laforet P, Kruijchaar ME, et al. Minutes of the European Pompe Consortium (EPOC) Meeting March 27 to 28, 2015, Munich, Germany. Acta Myol. 2015;34:141–3.

    PubMed  PubMed Central  Google Scholar 

  7. Nogales-Gadea G, Pinos T, Andreu AL, et al. Next-generation sequencing to estimate the prevalence of a great unknown: McArdle disease. Genet Med. 2015;17:679–80.

    Article  CAS  PubMed  Google Scholar 

  8. De Castro M, Johnston J, Biesecker L. Determining the prevalence of McArdle disease from gene frequency by analysis of next-generation sequencing data. Genet Med. 2015;17:1002–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Nogales-Gadea G, Brull A, Santalla A, Andreu AL, Arenas J, Martín MA, et al. McArdle Disease: update of reported mutations and polymorphisms in the PYGM gene. Hum Mutat. 2015;36:669–78.

    Article  CAS  PubMed  Google Scholar 

  10. Lucia A, Nogales-Gadea G, Pérez M, Martín MA, Andreu AL, Arenas J. McArdle disease: what do neurologists need to know? Nat Clin Pract Neurol. 2008;4:568–77.

    Article  PubMed  Google Scholar 

  11. Lucia A, Ruiz JR, Santalla A, Nogales-Gadea G, Rubio JC, García-Consuegra I, et al. Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. J Neurol Neurosurg Psychiatry. 2012;83:322–8.

    Article  PubMed  Google Scholar 

  12. De Kervoler E, Leroy-Willig A, Duboc D, et al. MR quantification of muscle fatty replacement in McArdle's disease. Magn Reson Imaging. 1996;14:1137–41.

    Article  Google Scholar 

  13. Jenenson P, Leroy-Willig A, De Kerviler E, et al. MR imaging as a potential diagnostic test for metabolic myopathies: importance of variations in the T2 of muscle with exercise. Am J Roentgenol. 1993;161:347–51.

    Article  Google Scholar 

  14. De Kerviler E, Leroy-Willig A, Jehenson P, et al. Exercise-induced muscle modifications: study of healthy subjects and patients with metabolic myopathies with MR imaging and P-31 spectroscopy. Radiology. 1991;181:259–64.

    Article  PubMed  Google Scholar 

  15. Dasouki M, Jawdat O, Almadhoun O, Pasnoor M, McVey AL, Abuzinadah A, et al. Pompe disease: literature review and case series. Neurol Clin. 2014;32:751–76.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, et al. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain. 2005;128:671–7.

    Article  CAS  PubMed  Google Scholar 

  17. Winkel LP, Hagemans ML, Van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, et al. The natural course of non-classic Pompe’s disease: a review of 225 published cases. J Neurol. 2005;252:875–84.

    Article  PubMed  Google Scholar 

  18. Figueroa-Bonaparte S, Segovia S, Llauger J, et al. Muscle MRI findings in childhood/adult onset Pompe disease correlate with muscle function. PLoS One. 2016;11:e0163493.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Horvath JJ, Austin SL, Case LE, et al. Correlation between quantitative whole‐body muscle magnetic resonance imaging and clinical muscle weakness in Pompe disease. Muscle Nerve. 2015;51:722–30.

    Article  Google Scholar 

  20. Van der Ploeg A, Carlier PG, Carlier R. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: the EMBASSY Study. Mol Genet Metab. 2016;119:115–23.

    Article  PubMed  CAS  Google Scholar 

  21. Angelini C. Spectrum of metabolic myopathies. Biochim Biophys Acta. 2015;1852:615–21.

    Article  CAS  PubMed  Google Scholar 

  22. Vissing J, Lukacs Z, Straub V. Diagnosis of Pompe disease: muscle biopsy vs blood-based assays. JAMA Neurol. 2013;70:923–7.

    Article  PubMed  Google Scholar 

  23. Laforet P, Nicolino M, Eymard B, et al. Juvenile and adult-onset acid maltase deficiency in France: Genotype-phenotype correlation. Neurology. 2000;55:1122–8.

    Article  CAS  PubMed  Google Scholar 

  24. Vieitez I, Teijeira S, Fernandez JM, et al. Molecular and clinical study of McArdle’s disease in a cohort of 123 European patients. Identification of 20 novel mutations. Neuromuscul Disord. 2011;21:817–23.

    Article  PubMed  Google Scholar 

  25. Martín MA, Lucía A, Arenas J, et al. Glycogen storage disease Type V. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews®. Seattle: University of Washington, Seattle; 2006. p. 1993–2018.

    Google Scholar 

  26. Fitzsimons RB. Facioscapulohumeral muscular dystrophy. Curr Opin Neurol. 1999;12:501–11.

    Article  CAS  PubMed  Google Scholar 

  27. Lemmers RJ, Tawil R, Petek LM, Balog J, Block GJ, Santen GW, et al. Digenic inheritance of an SMCHD1 mutations and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet. 2012;44:1370–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Sacconi S, Salviati L, Desnuelle C. Facioscapulohumeral muscular dystrophy. Biochim Biophys Acta. 2015;1852:607–14.

    Article  CAS  PubMed  Google Scholar 

  29. Wang LH, Tawil R. Facioscapulohumeral dystrophy. Curr Neurol Neurosci Rep. 2016; https://doi.org/10.1007/s11910-016-0667-0.

  30. Statland JM, Shah B, Henderson D, Van Der Maarel S, Tapscott SJ, Tawil R. Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies. Muscle Nerve. 2015;52:512–26.

    Article  CAS  Google Scholar 

  31. Confalonieri P, Oliva L, Andreetta F, Lorenzoni R, Dassi P, Mariani E, et al. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol. 2003;142:130–6.

    Article  CAS  PubMed  Google Scholar 

  32. Amato AA, Brown RF. Dysferlinopathies. In: Amato AA, Griggs RC, editors. Handbook of clinical neurology, vol. 101. Amsterdam: Elsevier; 2011. p. 111–8.

    Google Scholar 

  33. Fanin M, Angelini C. Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol. 2002;28:461–70.

    Article  CAS  PubMed  Google Scholar 

  34. Gayathri N, Alefia R, Nalini A, Yasha TC, Anita M, Santosh V, et al. Dysferlinopathy: spectrum of pathological changes in skeletal muscle tissue. Indian J Pathol Microbiol. 2011;54:350–4.

    Article  CAS  PubMed  Google Scholar 

  35. Gallardo E, Saenz A, Illa I. Limb-girdle muscular dystrophy 2A. In: Amato AA, Griggs RC, editors. Handbook of clinical neurology, vol. 101. Amsterdam: Elsevier; 2011. p. 97–110.

    Google Scholar 

  36. Schröder T, Fuchss J, Schneider I, Stoltenburg-Didinger G, Hanisch F. Eosinophils in hereditary and inflammatory myopathies. Acta Myol. 2013;32:148–53.

    PubMed  PubMed Central  Google Scholar 

  37. Paltiel AD, Ingvarsson E, Lee DK, Leff RL, Nowak RJ, Petschke KD, et al. Demographic and clinical features of inclusion body myositis in North America. Muscle Nerve. 2015;52:527–33.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, Maisonobe T, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134:3176–84.

    Article  PubMed  Google Scholar 

  39. Cortese A, Machado P, Morrow J, Dewar L, Hiscock A, Miller A, et al. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscul Disord. 2013;23:404–12.

    Article  CAS  PubMed  Google Scholar 

  40. Benveniste O, Stenzel W, Hilton-Jones D, Sandri M, Boyer O, Van Engelen BG. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol. 2015;129:611–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134:3167–75.

    Article  PubMed  Google Scholar 

  42. Dimachkie MM, Barohn RJ. Inclusion body myositis. Neurol Clin. 2014;32:629–64.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Hilton-Jones D. Diagnosis and treatment of inflammatory muscle diseases. J Neurol Neurosurg Psychiatry. 2003;74(Suppl 2):25–31.

    Google Scholar 

  44. Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, et al. Pilot trial of etanercept in the treatment of inclusion body myositis. Neurology. 2006;66(Suppl 1):123–4.

    Article  Google Scholar 

  45. Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132:1536–44.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;3:323–7.

    Article  Google Scholar 

  47. Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci. 2012;334:123–5.

    Article  CAS  Google Scholar 

  48. Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology. 2004;63:718–20.

    Article  CAS  Google Scholar 

  49. Alexanderson H. Exercise in inflammatory myopathies, including inclusion body myositis. Curr Rheumatol Rep. 2012;14:244–51.

    Article  CAS  PubMed  Google Scholar 

  50. Johnson LG, Collier KE, Edwards DJ, Philippe DL, Eastwood PR, Walters SE, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis. 2009;10:178–84.

    Article  PubMed  Google Scholar 

  51. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course and outcome in PM and sporadic IBM. Neurology. 2008;70:418–24.

    Article  PubMed  Google Scholar 

  52. Girolamo F, Lia A, Amati A, Strippoli M, Coppola C, Virgintino D, et al. Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis. Neuropathol Appl Neurobiol. 2013;39:736–49.

    Article  CAS  PubMed  Google Scholar 

  53. Maurage CA, Bussière T, Sergeant N, Ghesteem A, Figarella-Branger D, Ruchoux MM, et al. Tau aggregates are abnormally phosphorylated in inclusion body myositis and have an immunoelectrophoretic profile distinct from other tauopathies. Neuropathol Appl Neurobiol. 2004;30:624–34.

    Article  CAS  PubMed  Google Scholar 

  54. Vattemi G, Nogalska A, King Engel W, D’Agostino C, Checler F, Askanas V. Amyloid-beta42 is preferentially accumulated in muscle fibers of patients with sporadic inclusion-body myositis. Acta Neuropathol. 2009;117:569–74.

    Article  CAS  PubMed  Google Scholar 

  55. Hori H, Yamashita S, Tawara N, Hirahara T, Kawakami K, Nishikami T, et al. Clinical features of Japanese patients with inclusion body myositis. J Neurol Sci. 2014;346:133–7.

    Article  PubMed  Google Scholar 

  56. Cox FM, Reijnierse M, Van Rijswijk CS, Wintzen AR, Verschuuren JJ, Badrising UA. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology. 2011;50:1153–6.

    Article  PubMed  Google Scholar 

  57. Tasca G, Monforte M, De Fino C, Kley RA, Ricci E, Mirabella M. MRI pattern recognition in sporadic inclusion body myositis. Muscle Nerve. 2015;52:956–62.

    Article  PubMed  Google Scholar 

  58. Herbert MK, Stammen-Vogelzangs J, Verbeek MM, Rietveld A, Lundberg IE, Chinoy H, et al. Disease specificity of autoantibodies to cytosolic 5′-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune disease. Ann Rheum Dis. 2016;75:696–701.

    Article  CAS  PubMed  Google Scholar 

  59. Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, Tiniakou E, Petri M, Baer A, et al. Cytosolic 5′-nucleotidase 1A is a common target of circulating autoantibodies in several autoimmune diseases. Arthritis Care Res. 2016;68:66–71.

    Article  CAS  Google Scholar 

  60. Larman HB, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al. Cytosolic 5-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013;73:408–18.

    Article  PubMed  CAS  Google Scholar 

  61. Pluk H, Van Hoeve BJ, Van Dooren SH, Stammen-Vogelzangs J, Van Der Heijden A, Schelhaas HJ, et al. Autoantibodies to cytosolic 5’-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;73:397–407.

    Article  CAS  PubMed  Google Scholar 

  62. Eslamian F, Bahrami A, Aghamohammadzadeh N, Niafar M, Salekzamani Y, Behkamrad K. Electrophysiologic changes in patients with untreated primary hypothyroidism. J Clin Neurophysiol. 2011;28:323–8.

    Article  PubMed  Google Scholar 

  63. Khedr EM, El Toony LF, Tarkhan MN, Abdella G. Peripheral and central nervous system alterations in hypothyroidism: electrophysiological findings. Neuropsychobiology. 2000;41:88–94.

    Article  CAS  PubMed  Google Scholar 

  64. Duyff RF, Van Den Bosch J, Laman DM, Van Loon BJ, Linssen WH. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry. 2000;68:750–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Tiniakou E, Mammen AL. Necrotizing myopathy causes by central hypothyroidism. Muscle Nerve. 2015;52:152–3.

    Article  PubMed  Google Scholar 

  66. Anwar S, Gibofsky A. Musculoskeletal manifestations of thyroid disease. Rheum Dis Clin N Am. 2010;36:637–46.

    Article  Google Scholar 

  67. Chawla J. Stepwise approach to myopathy in systemic disease. Front Neurol. 2011;2:1–10.

    Google Scholar 

  68. Dyck PJ, Thaisetthawatkul P. Lumbosacral plexopathy. Continuum. 2014;20(5):1343–58.

    PubMed  Google Scholar 

  69. Abdel-Hamid A, Oddis CV, Lacomis D. Severe hydroxychloroquine myopathy. Muscle and Nerve 2008;38:1206–10.

    Article  Google Scholar 

  70. Kunal RW, Romano GJ. Toxic myopathies. In: Katirji B, Kaminski HJ, Ruff R, editors. Neuromuscular disorders in clinical practice. 2nd ed. New York: Springer; 2014. p. 1365–88.

    Google Scholar 

  71. Estes ML, Ewing-Wilson D, Chou SM, Mitsumoto H, Hanson M, Shirey E, et al. Chloroquine neuromyotoxicity - clinical and pathologic perspective. Am J Med. 1987;82:447–55.

    Article  CAS  PubMed  Google Scholar 

  72. Casado E, Gratacós J, Tolosa C, Martínez JM, Ojanguren I, Ariza A, et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis. 2006;65:385–90.

    Article  CAS  PubMed  Google Scholar 

  73. Pulipaka U, Lacomis D, Omalu B. Amiodarone-induced neuromyopathy: three cases and a review of the literature. J Clin Neuromuscul Dis. 2002;3:97–105.

    Article  PubMed  Google Scholar 

  74. Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy. 2004;24:1784–92.

    Article  PubMed  Google Scholar 

  75. Cantarini L, Volpi N, Galeazzi M, Giani T, Fanti F, Lucherini OM, et al. Colchicine myopathy and neuromyopathy: two cases with different characteristics. J Clin Rheumatol. 2010;16:229–32.

    Article  PubMed  Google Scholar 

  76. Mhiri C, Baudrimont M, Bonne G, Geny C, Degoul F, Marsac C, et al. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol. 1991;29:606–14.

    Article  CAS  PubMed  Google Scholar 

  77. Simpson DM, Slasor P, Dafni U, Berger J, Fischl MA, Hall C. Analysis of myopathy in a placebo-controlled zidovudine trial. Muscle Nerve. 1997;20:382–5.

    Article  CAS  PubMed  Google Scholar 

  78. Casademont J, Barrientos A, Grau JM, Pedrol E, Estivill X, Urbano-Márquez A, et al. The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction. Brain. 1996;119:1357–64.

    Article  PubMed  Google Scholar 

  79. Preedy VR, Adachi J, Ueno Y, Ahmed S, Mantle D, Mullatti N, et al. Alcoholic skeletal myopathy: definitions, features, contribution of neuropathy, impact and diagnosis. Eur J Neurol. 2001;8:677–87.

    Article  CAS  PubMed  Google Scholar 

  80. Estruch R, Sacanella E, Fernández-Solá J, Nicolás JM, Rubin E, Urbano-Márquez A. Natural history of alcoholic myopathy: a 5-year study. Alcohol Clin Exp Res. 1998;22:2023–8.

    CAS  PubMed  Google Scholar 

  81. Salami JA, Warraich H, Valero-Elizondo J, Spatz ES, Desai NR, Rana JS, et al. National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey. JAMA Cardiol. 2016; https://doi.org/10.1001/jamacardio.2016.4700.

    Article  PubMed  Google Scholar 

  82. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–14.

    Article  CAS  PubMed  Google Scholar 

  83. Khan A, Maki KC, Ito MK, Cohen JD, Sponseller CA, Bell M, et al. Statin associated muscle symptoms: characteristics of patients and recommendations by providers. J Clin Lipidol. 2015;9:460.

    Article  CAS  Google Scholar 

  84. Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012;23:317–24.

    Article  CAS  PubMed  Google Scholar 

  85. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy— a genomewide study. N Engl J Med. 2008;359:789–99.

    Article  CAS  PubMed  Google Scholar 

  86. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 17,000 participants in 26 randomized trials. Lancet. 2010;376:1670–81.

    Article  CAS  Google Scholar 

  87. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association’s Muscle Safety Expert Panel. An assessment by the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8:S58–71.

    Article  PubMed  Google Scholar 

  88. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(Suppl 1):52–60.

    Article  CAS  Google Scholar 

  89. García-Rodríguez LA, Massó-González EL, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf. 2008;17:943–52.

    Article  PubMed  CAS  Google Scholar 

  90. Mampuya WM, Frid D, Rocco M, Huang J, Brennan DM, Hazen SL, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597–603.

    Article  PubMed  PubMed Central  Google Scholar 

  91. McKenney JM, Davidson MH, Jacobson TA, Guyton JR, National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the national lipid association statin safety assessment task force. Am J Cardiol. 2006;97:S89–94.

    Article  CAS  Google Scholar 

  92. Armour R, Zhou L. Outcomes of statin myopathy after statin withdrawal. J Clin Neuromuscul Dis. 2013;14:103–9.

    Article  PubMed  Google Scholar 

  93. Mohaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer K, et al. Association between statin-associated myopathy and skeletal muscle damage. Can Med Assoc J. 2009;181:E11–8.

    Article  Google Scholar 

  94. Khaleeli AA, Edwards RHT, Gohil K, McPhail G, Rennie MJ, Round J, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol. 1983;18:155–66.

    Article  CAS  Google Scholar 

  95. Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011;78:41–4.

    Article  CAS  PubMed  Google Scholar 

  96. Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol. 1985;76:234–42.

    Article  CAS  PubMed  Google Scholar 

  97. Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology. 1997;48:1234–8.

    Article  CAS  PubMed  Google Scholar 

  98. Dropcho EJ, Soong S. Steroid-induced weakness in patients with brain tumors. Neurology. 1991;41:1235–9.

    Article  CAS  PubMed  Google Scholar 

  99. Cohen BH. Neuromuscular and systemic presentations in adults: diagnoses beyond MERRF and MELAS. Neurotherapeutics. 2013;10:227–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Milone M, Wong LJ. Diagnosis of mitochondrial myopathies. Mol Genet Metab. 2013;110:35–41.

    Article  CAS  PubMed  Google Scholar 

  101. Finsterer J, Löscher WN, Wanschitz J, Quasthoff S, Grisold W. Secondary myopathy due to systemic diseases. Acta Neurol Scand. 2016;134:388–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Harlan Michelle

  2. Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Expression, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA

    Andrew L. Mammen

Authors
  1. Harlan Michelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew L. Mammen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew L. Mammen .

Editor information

Editors and Affiliations

  1. Division of Rheumatology and Clinical Immunology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA

    Rohit Aggarwal

  2. Division of Rheumatology and Clinical Immunology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA

    Chester V. Oddis

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Michelle, H., Mammen, A.L. (2020). Myositis Mimics: The Differential Diagnosis of Myositis. In: Aggarwal, R., Oddis, C. (eds) Managing Myositis. Springer, Cham. https://doi.org/10.1007/978-3-030-15820-0_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-15820-0_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-15819-4

  • Online ISBN: 978-3-030-15820-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation